title: Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease.
abstract: BACKGROUND
  HMG-CoA reductase inhibitors (statins) have antiatherogenic effects beyond their cholesterol-lowing effect. Whether atorvastatin has a stronger antioxidant effect than other statins is uncertain.
  
  
  OBJECTIVE
  To determine the effects of simvastatin and atorvastatin on markers of oxidative stress in patients with coronary heart disease (CHD).
  
  
  METHODS
  This study was comprised of 164 patients with CHD and a control population of 122 healthy subjects. The patients with CHD were divided into 2 groups and treated with either simvastatin 20 mg/day or atorvastatin 10 mg/day. The markers of oxidative stress were measured before and after 12 weeks of treatment.
  
  
  RESULTS
  The effects of atorvastatin on reducing oxidative stress were significantly greater compared with those of simvastatin (P < 0.05). The changes in the markers of oxidative stress did not correlate with the changes in the plasma lipid profile (P > 0.05).
  
  
  CONCLUSIONS
  This study suggests that atorvastatin reduces oxidative stress more effectively than simvastatin.
authors.affiliation: Department of Cardiac Care Unit, The First Affiliated Hospital of Harbin Medical University, Harbin, China. wlfeng@hotmail.com
authors.forename: Jia
authors.initials: J
authors.lastname: Li
authors.forename: Yan-Ming
authors.initials: YM
authors.lastname: Sun
authors.forename: Lan-Feng
authors.initials: LF
authors.lastname: Wang
authors.forename: Zhu-Qin
authors.initials: ZQ
authors.lastname: Li
authors.forename: Wei
authors.initials: W
authors.lastname: Pan
authors.forename: Hong-Yan
authors.initials: HY
authors.lastname: Cao
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D000069059:Atorvastatin; D015415:Biomarkers / Q000097:blood; D016009:Chi-Square Distribution; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology*; D018752:Diet, Fat-Restricted; D005260:Female; D005978:Glutathione / Q000097:blood; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008111:Liver Function Tests; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D011446:Prospective Studies; D011758:Pyrroles / Q000627:therapeutic use*; D019821:Simvastatin / Q000627:therapeutic use*; D013482:Superoxide Dismutase / Q000097:blood; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D008315:Malondialdehyde; D000069059:Atorvastatin; D019821:Simvastatin; D013482:Superoxide Dismutase; D005978:Glutathione
references.citation: Clin Pharmacol Ther. 2008 Jan;83(1):37-51
references.pmid: 18043680
references.citation: Atherosclerosis. 2007 Jun;192(2):432-7
references.pmid: 17239888
references.citation: Atherosclerosis. 2008 Oct;200(2):229-38
references.pmid: 18490019
references.citation: Pediatr Res. 2007 Oct;62(4):456-61
references.pmid: 17667843
references.citation: Circ J. 2008 May;72(5):807-12
references.pmid: 18441463
references.citation: Curr Atheroscler Rep. 2007 Jan;9(1):33-41
references.pmid: 17169243
references.citation: Evid Based Cardiovasc Med. 2006 Jun;10(2):135-7
references.pmid: 16753534
references.citation: Circulation. 2001 Jan 2;103(1):113-8
references.pmid: 11136695
references.citation: Diabetes. 2008 Nov;57(11):2992-8
references.pmid: 18678613
references.citation: Am J Cardiol. 2003 Feb 6;91(3A):7A-11A
references.pmid: 12645638
references.citation: Cardiovasc Ther. 2008 Summer;26(2):166-78
references.pmid: 18485137
references.citation: Int J Clin Pract. 2006 Mar;60(3):308-14
references.pmid: 16494646
references.citation: Circ Res. 2004 Jul 23;95(2):217-23
references.pmid: 15178637
references.citation: Arch Med Res. 2007 Jul;38(5):479-88
references.pmid: 17560452
references.citation: Curr Alzheimer Res. 2005 Jul;2(3):343-53
references.pmid: 15974900
references.citation: Mayo Clin Proc. 2008 Dec;83(12):1316-25
references.pmid: 19046550
references.citation: Clin Chem. 2006 Mar;52(3):446-52
references.pmid: 16384883
references.citation: Clin Exp Pharmacol Physiol. 2008 Jul;35(7):820-6
references.pmid: 18430061
references.citation: Methods Enzymol. 1984;105:114-21
references.pmid: 6727659
references.citation: Clin Biochem. 2008 Sep;41(13):1067-73
references.pmid: 18634772
references.citation: Drugs. 2007;67 Suppl 1:43-54
references.pmid: 17910520
references.citation: J Am Coll Nutr. 2007 Jun;26(3):225-32
references.pmid: 17634167
references.citation: Am J Cardiol. 2008 Jun 2;101(11A):57E-62E
references.pmid: 18514628
references.citation: Am J Cardiol. 1997 Jul 1;80(1):106-7
references.pmid: 9205036
references.citation: Atherosclerosis. 2008 May;198(1):65-76
references.pmid: 18061195
references.citation: Br J Clin Pharmacol. 2004 May;57(5):640-51
references.pmid: 15089818
references.citation: Clin Exp Pharmacol Physiol. 2008 May;35(5-6):625-9
references.pmid: 18177480
references.citation: Lancet. 2005 May 21-27;365(9473):1779-85
references.pmid: 15910950
references.citation: Clin Chem. 1995 Jun;41(6 Pt 1):892-6
references.pmid: 7768008
references.citation: J Nephrol. 2008 Nov-Dec;21(6):924-30
references.pmid: 19034878
references.citation: Lipids. 2007 Nov;42(11):999-1009
references.pmid: 17713803
references.citation: Angiology. 2006 Mar-Apr;57(2):211-8
references.pmid: 16518530
references.citation: J Trace Elem Med Biol. 2005;19(1):61-7
references.pmid: 16240674
references.citation: Eur J Cardiovasc Prev Rehabil. 2007 Aug;14(4):495-500
references.pmid: 17667637
references.citation: Am J Cardiol. 2009 Mar 1;103(5):577-82
references.pmid: 19231315
references.citation: Indian J Clin Biochem. 1999 Jul;14(2):176-83
references.pmid: 23105216
references.citation: Clin Chem. 1988 Mar;34(3):497-500
references.pmid: 3349599
references.citation: J Cardiovasc Pharmacol. 2008 Mar;51(3):311-6
references.pmid: 18356697